经皮雄激素治疗雄激素缺乏相关干眼的随机对照双盲研究
结果显示AndroGel组眼表疾病指数、泪膜破裂时间、角膜荧光素染色和Schirmer试验均较安慰剂组显著改善,女性血清睾酮显著升高,未报告严重不良事件。
要点
- 经皮雄激素治疗4周可显著改善雄激素缺乏干眼患者的症状和体征。
- AndroGel组20%出现油性皮肤、4%出现痤疮,无严重不良事件。
- 女性患者血清睾酮显著升高,男性睾酮及两组性激素结合球蛋白无差异。
核心结论
- 经皮雄激素可有效缓解老年干眼患者的症状和体征并改善生活质量,短期治疗无严重副作用。
主要发现
- 治疗4周后AndroGel组眼表疾病指数较安慰剂组显著下降(-14.36 ± 7.76 vs 0.14 ± 14.60,P < .001)。
- AndroGel组泪膜破裂时间(7.40 ± 3.37 vs -1.14 ± 1.68秒,P < .001)、角膜荧光素染色(-0.62 ± 0.30 vs 0.19 ± 0.37,P < .001)和Schirmer试验(6.84 ± 5.10 vs -0.48 ± 2.14 mm,P < .001)均较安慰剂组显著改善。
- 女性患者血清睾酮在AndroGel组较安慰剂组显著升高(P < .001),男性血清睾酮及两组性激素结合球蛋白无差异。
- AndroGel组20%患者出现油性皮肤、4%出现痤疮,未报告严重不良事件。
- AndroGel组绝经评分较安慰剂组显著改善(P < .001),而老年男性症状评分两组无差异(P = .589)。
临床怎么用
- 对于雄激素缺乏相关干眼的老年患者,可考虑短期经皮雄激素治疗以改善症状、体征和生活质量。
- 治疗期间需关注油性皮肤和痤疮等不良反应,女性患者需监测血清睾酮变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy, safety, and quality of life (QOL) of transdermal androgen in treatment of dry eye patients associated with androgen deficiency. DESIGN: Randomized controlled trial. METHODS: Fifty patients with dry eye from a tertiary eye center in northern Thailand were randomized to receive transdermal androgen (AndroGel; Besins Healthcare, Brussels, Belgium) or placebo for 4 weeks. Main outcome measures were symptoms and signs of dry eye. Serum level of sex hormone and QOL questionnaires were also evaluated at the baseline and after treatment. RESULTS: After 4 weeks, the Ocular Surface Disease Index decreased significantly in the AndroGel group compared to the placebo (-14.36 ± 7.76 vs 0.14 ± 14.60, P < .001). Significant improvements of tear break-up time (7.40 ± 3.37 vs -1.14 ± 1.68 seconds, P < .001), corneal fluorescein staining (-0.62 ± 0.30 vs 0.19 ± 0.37, P < .001), and Schirmer test (6.84 ± 5.10 vs -0.48 ± 2.14 mm, P < .001) were observed in the AndroGel group compared to the placebo. Serum testosterone in female patients significantly increased in the AndroGel group compared to the placebo (P < .001), while no different change was observed in serum testosterone in male subjects and the sex hormone-binding globulin in both groups. In the AndroGel group, 20% of patients had oily skin and 4% had acne. No serious adverse effects were reported. The menopause rating score improved significantly in the AndroGel group compared to the placebo (P < .001), while the aging male symptoms were not different in both groups (P = .589). CONCLUSIONS: Transdermal androgen was effective in relieving symptoms and signs of dry eye as well as improving QOL in aging patients. There were no serious side effects during a short-term treatment.
引用
- Supalaset S, Tananuvat N, Pongsatha S, et al. A Randomized Controlled Double-Masked Study of Transdermal Androgen in Dry Eye Patients Associated With Androgen Deficiency. Am J Ophthalmol. 2018. PMID: 30268865. doi:10.1016/j.ajo.2018.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。